Archive · 18 Aug 2025
Alembic Receives USFDA Nod for Acne Treatment Drug
Alembic Pharmaceuticals can now sell a generic medicine for pimples (acne vulgaris) after getting permission from the US government.
This medicine, Tretinoin Cream, is the same as a brand-name version already sold in the US.
This means more people can get this treatment.
The market for this type of medicine is about $94 million.
The company's stock price went up a little bit after this news.
Alembic Pharmaceuticals received USFDA approval for Tretinoin Cream USP (0.025%).
The drug is a generic version for acne vulgaris treatment.
It is therapeutically equivalent to Retin-A Cream (0.025%) from Bausch Health.
The market size for this drug is approximately $94 million (ending June 2025).
Alembic's shares increased by 1.03% after the announcement.
- Who
- Alembic Pharmaceuticals and the USFDA.
- What
- Alembic Pharmaceuticals received USFDA approval for Tretinoin Cream USP (0.025%) to treat acne vulgaris.
- When
- The approval was announced on August 18, 2025.
- Where
- In the US market.
- Why
- To allow Alembic to market a generic treatment for acne.
- Drug Name
- Tretinoin Cream USP (0.025%)
- Approval Authority
- USFDA
- Purpose
- Treatment of acne vulgaris
- Therapeutic Equivalence
- Retin-A Cream (0.025%)
- Estimated Market Size
- $94 million (ending June 2025)
- Company Stock Movement
- Up 1.03%